


EC5026

## Chemical Properties

CAS No. : 1809885-32-2  
 Formula: C<sub>18</sub>H<sub>23</sub>F<sub>4</sub>N<sub>3</sub>O<sub>3</sub>  
 Molecular Weight: 405.39  
 Appearance: no data available  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

Description	EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
Targets(IC50)	Epoxide Hydrolase
In vivo	EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids. Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators. sEH inhibitors developed by EicOsis have already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses.

## Solubility Information

Solubility	DMSO: 250 mg/mL (616.69 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4668 mL	12.3338 mL	24.6676 mL
5 mM	0.4934 mL	2.4668 mL	4.9335 mL
10 mM	0.2467 mL	1.2334 mL	2.4668 mL
50 mM	0.0493 mL	0.2467 mL	0.4934 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286    E\_mail:info@targetmol.com    Address:36 Washington Street,Wellesley Hills,MA 02481